scriptors and assessment categories [11] . This lexicon is based on the results of the International Working Group on Breast MRI and the American College of Radiology (ACR) Breast MRI Lexicon Committee and includes a BI-RADS 3 assessment category [11] [12] [13] [14] . However, the particular MRI features of the lesions that may be placed in this category and the acceptable cancer yield are not clearly defined. Indeed, there is a paucity of published literature pertaining to this MRI assessment. Five articles have included data on the MRI BI-RADS 3 assessment category, with a resulting wide range of cancer yields (0.6-10%) [15] [16] [17] [18] [19] . Additional research is needed to determine whether there are distinct morphologic or kinetic characteristics that can be defined as appropriate to warrant the MRI BI-RADS 3 assessment. This is especially important now that the American Cancer Society is recommending annual screening breast MRI in addition to
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mammography for patients with a lifetime risk of malignancy that exceeds 20% because a dramatic increase in the number of MRI examinations is expected nationwide. Given the high cost of breast MRI and MRIguided biopsy, it is critical that we strive to determine the appropriate features and follow-up interval of MRI BI-RADS 3 lesions so that unnecessary biopsy and follow-up imaging can be minimized.
The purpose of this study is to examine the morphologic and kinetic characteristics and outcomes of lesions assessed as BI-RADS 3 at our institution and to extrapolate which lesions are appropriate for placement into this category and short-interval follow-up MRI.
Materials and Methods

Data Collection
Data were obtained from our established computerized clinical MRI database. This database includes detailed prospectively collected information about all breast MRI examinations conducted at our institution since January 1, 2003. Our radiologists use a data form based on the ACR BI-RADS breast MRI lexicon to record their findings at the time of MRI interpretation [11] . One data form is completed for each BI-RADS finding, which can result in multiple assessments for each breast in the database. For example, a single examination may receive a BI-RADS 6 for a known carcinoma, a BI-RADS 3 for a separate finding, and a BI-RADS 2 for a known enhancing fibroadenoma. Quality control reviews are conducted quarterly to identify data entry error, form completion error, and comprehensiveness of the database.
Case Selection
Institutional review was obtained for this HIPAA-compliant study (Fred Hutchinson Cancer Research Center CCIRB 6264). We performed a retrospective review of 2,569 consecutive breast MRI examinations acquired in 1,735 women at our institution from January 2003 through November 2006. Many women who underwent breast MRI for the clinical indication of high-risk screening had multiple examinations over the course of the study period.
We defined the study cohort as those lesions with a BI-RADS 3 assessment and recommendation for a short interval (6 months) follow-up MRI. We queried the database for all examinations that received one or more MRI BI-RADS 3 assessments to create the analysis set. This set included the 809 consecutive examinations in 678 patients acquired from January 2003 through June 2004 that we reported on in our previous study of probably benign MRI findings [15] .
For all study cases, we recorded the clinical indication and the date of the examination. We then reviewed all available electronic imaging, pathology, and clinical records through May 2008 to determine if the lesions were benign or malignant. If a biopsy of the lesion was performed at our institution within 12 months, histopathology was used to determine the outcome. If the patient had a benign or negative follow-up MRI within 18 months, the lesion was considered benign. If the patient did not have a benign follow-up MRI or a biopsy at our institution, outcomes were determined by linkage to the Consortium Oncology Data Integration (CODI) project, which contains data from the Cancer Surveillance System (CSS) of the National Cancer Institute Surveillance, Epidemiology, and End Results database. Lesions were categorized as malignant if a malignant correlate for the study lesion was identified in CODI within 12 months of the index MRI. Lesions were considered benign if there was no correlate for the study lesion identified in CODI within 12 months of the index MRI. We recorded the date of the follow-up breast MRI, the BI-RADS assessment category on follow-up, and the pathology result from needle biopsy or surgery if present.
MRI Acquisition Protocols
All study examinations were performed on an LX 1.5-T scanner (GE Healthcare) using a dedicated bilateral breast coil. Four different acquisition protocols were used during the period of this study. Each imaging protocol included a bilateral axial localizer sequence: one before and at least two after contrast-enhanced sagittal T1-weighted fat-suppressed 3D fast spoiled gradient-recalled (3D FSPGR) acquisitions. Scanning parameters common to all protocols included a field of view (FOV) of 18-22 cm depending on patient size; slice thickness, ≤ 3 mm; and 256 × 192 matrix. Axial and coronal reformations as well as maximum intensity projections (MIPs) were constructed from the first contrast-enhanced series.
From Patients with silicone breast implants underwent the entirety of one of the above protocols, depending on the date, with the addition of a water-suppressed STIR sequence to evaluate implant integrity.
All MRI examinations were processed with breast MRI computer-aided evaluation (CAE) software (CADstream, version 3.0, Confirma). The examinations were reviewed simultaneously on the PACS monitors and dedicated CAE workstation.
Clinical Breast MRI Interpretation
Four fellowship-trained breast imagers with breast MRI experience interpreted examinations during the study period. Clinical history, previous imaging, and reports were available to the interpreting radiologist. MRI interpretation criteria, assessments, and recommendations were based on the ACR BI-RADS MRI lexicon [11] . Consistent with the BI-RADS lexicon, there were no defined prospective criteria for BI-RADS 3 MRI lesions. Each radiologist was free to assess lesions as probably benign as appropriate. Lesion morphology and kinetic characteristics were recorded, including delayed phase enhancement categorized by single most suspicious type of lesion kinetics (any washout > any plateau > any persistent).
Statistical Analysis
The MRI database provided the clinical indication, dates of the index and follow-up examinations, and BI-RADS assessments. Follow-up data from the clinical records, such as mastectomy and pathology, were entered into a Microsoft Excel
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spreadsheet and then imported into SAS statistical software (version 9.2) for analysis. Characteristics of BI-RADS 3 lesions were analyzed, and summary statistics including frequencies, means, and ranges were computed. Clinical indications for examinations, frequency of BI-RADS 3 use, followup compliance, and cancer yield were analyzed. Frequency of use was defined as the number of MRI examinations receiving at least one recommendation for a 6-month follow-up MRI divided by the total number of MRI examinations. Followup compliance was defined as the percentage of the study cohort patients who underwent the recommended follow-up MRI at our institution within the study period. The time to follow-up was defined as the number of months between the first MRI with a recommendation for short interval follow-up and the follow-up MRI. It was calculated only for those patients who returned for the follow-up MRI at our institution. Cancer yield was defined as the percentage of the study cohort with pathologically confirmed malignancy corresponding to the MRI findings.
Results
BI-RADS 3 Interpretation Frequency and Patient Characteristics
We identified 362 lesions that received a BI-RADS 3 assessment and a recommendation for a 6-month follow-up MRI during the study period. These lesions occurred in 260 (10.1%) of 2,569 examinations performed in 236 (13.6%) of 1,735 patients (Fig. 1) . The lesions outnumbered the patients because each patient could have more than one BI-RADS 3 lesion. There were 141 patients with one lesion, 74 patients with two lesions, and 21 patients with three or more BI-RADS 3 lesions. Our patient population included 236 women with an average age of 50 years (age range, 20-85 years). The clinical indications for the 260 examinations assigned BI-RADS 3 were to evaluate the extent of disease in 119 (46%), high-risk screening in 61 (23%), problem solving in 25 (10%), implants in six (2%), and other indications in 17 (7%). In addition, 32 (12%) of 260 examinations were performed during the study to satisfy recommendations for short-interval followup in patients who had previously received a BI-RADS 3 lesion assessment (Table 1) .
Probably Benign MRI Lesion Characteristics
The 362 BI-RADS 3 lesions included 168 (46%) foci, 132 (36%) nonmasslike enhancements (NMLEs), and 62 (17%) masses (Table 2). Size data were available for 318 of the lesions, and 223 (70%) were smaller than 1 cm. The morphologies of the foci were not described because, by definition, they are tiny areas of enhancement that cannot be further characterized. The maximum dimension of the 132 NMLE lesions was between 3 and 100 mm, with a mean of 27 mm and a median of 20 mm. The NMLE lesions were most often described as a focal area (29%), diffuse (25%), or regional (17%). The majority of NMLE lesions were reported as heterogeneous (36%), clumped (28%), or homogeneous (20%). The maximum dimension of the 62 mass lesions was between 3 and 42 mm with a mean of 9 mm and a median of 7 mm. Seventy-four percent of masses were round or oval, 65% had homogeneous enhancement, and 78% showed smooth margins. Delayed kinetic information was available in 275 (76%) of 362 study lesions (Table  3 ). The majority (164 of 275, 60%) showed persistent enhancement as the most suspicious kinetic curve type. Some lesions with plateau (47 of 275, 17%) or washout (64 of 275, 23%) kinetics were also assessed as probably benign.
Lesion Follow-Up
Follow-up with recommended imaging or tissue sampling at our institution was performed in 146 (61.9%) of 236 patients with (Fig. 1) . First imaging follow-up occurred between 11 and 630 days after the index MRI, with a median of 209 days and a mean of 240 days. There was no subsequent diagnosis of malignancy in any of these patients over the course of the study period.
The 12 lesions that underwent tissue sampling included eight foci, four NMLE lesions, and no masses. Histology from 12 lesions was acquired at our center via mastectomy in three, lumpectomy in one, core needle biopsy in seven, and skin punch biopsy in one. The results included nine benign findings, one low-grade ductal carcinoma in situ (DCIS) in a focus, one high-grade DCIS in NMLE, and one atypical ductal hyperplasia (ADH) in NMLE that could be directly correlated to the MRI findings (Table 4) .
Ninety (38.1%) of 236 patients did not return to our institution for the recommended follow-up MRI, and a query of the CODI database was performed for all of them (Fig. 1) . There was no match in the CODI database for 86 (95.6%) of 90 patients with 139 (95.9%) of 145 BI-RADS 3 lesions. None of these patients had any type of tissue match in the CODI during the follow-up period. Four patients with six lesions did have a tissue record in the NMLE database. However, after review of the NMLE information and the MRI information by a radiologist, the biopsy location could not definitely be correlated to the location of the MRI finding. For three lesions, the side of the biopsy (right vs left) did not match the side of the MRI finding. For the other three lesions, the location of the lesion could not be determined from the CODI information. There were no malignant histology results in the CODI database that matched any of the lesions that did not receive followup at our institution.
Malignant and High-Risk Lesions
One high-risk lesion (ADH) and two cancers (both DCIS) were diagnosed in probably benign lesions in our study population. A 51-year-old patient had a diagnosis of ADH in a probably benign lesion that was described as diffuse heterogeneous NMLE. The initial examination was performed to evaluate the extent of her newly discovered ipsilateral cancer and the ADH was found when she underwent mastectomy. A 32-year-old patient had a lesion described as heterogeneous NMLE in a diffuse distribution on MRI performed to evaluate the extent of disease after a new diagnosis of breast cancer in the ipsilateral breast (Table 4) . High-grade DCIS was discovered in the mastectomy specimen at the site of the probably benign lesion. The other malignancy occurred in a 44-year-old patient who underwent initial MRI to evaluate the extent of disease for a new diagnosis of DCIS. She had a focus of enhancement in the contralateral breast that was originally assessed BI-RADS 3 and followed over successive MRI examinations (Fig. 2) . Initial evaluation showed a 5-mm focus with washout kinetics. The subsequent MRI examinations revealed washout kinetics along with enlargement of the lesion and the description was changed to NMLE with an upgrade to BI-RADS 4. A diagnosis of low-grade DCIS was made from MRI-guided vacuum-assisted breast biopsy. The overall cancer yield was thus two (0.85%) for all 236 patients in the study.
Discussion
The use of the MRI BI-RADS 3 probably benign assessment is common in clinical practice despite the lack of specific morphologic and kinetic criteria ( Table 5 ). The probably benign assessment has been applied to 17-24% of patients and 6.6-12% of examinations 
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in previous studies [15] [16] [17] [18] [19] . It should be noted that some of these studies (Kriege et al. [18] and Kuhl et al. [19] ) reported an examination as probably benign only if BI-RADS 3 was the most suspicious assessment given for any lesion in the examination. Our study, however, includes all probably benign assessments for any study even when more suspicious assessments (such as BI-RADS 4 or 5) were provided for other lesions. Previous research indicates a wide range of cancer yields (0.6-10%) among probably benign MRI lesions [15] [16] [17] [18] [19] . Our data show a low cancer yield (0.85%) among patients with probably benign lesions. These findings suggest that the use of a BI-RADS 3 assessment in our practice is a safe alternative to biopsy. However, the findings may also indicate that we unnecessarily place many benign or normal findings into the probably benign category. Such a strategy, although cautious, may result in overutilization of expensive medical resources and unnecessary anxiety for patients. The mammographic BI-RADS 3 category was implemented when repeating a quick and relatively inexpensive mammography could obviate a more costly trip to the operating room for surgical excisional biopsy. Considering the need for preoperative and postoperative appointments, risk of general anesthesia, possible undesirable cosmetic outcomes, and morbidity of the procedure, the potential benefit of the BI-RADS 3 category for 98% of patients with benign lesions is large. However, as we evaluate the relative merits of shortterm follow-up MRI, we should consider that the potential benefit is not as great.
Compared with follow-up mammography, follow-up breast MRI is more expensive, takes more time, and requires IV contrast administration. Percutaneous biopsy techniques allow radiologists to acquire tissue samples without a visit to a surgeon or an intraoperative procedure. The risks of undesirable cosmetic outcomes are reduced along with morbidity. Compared with an operation, percutaneous tissue sampling is faster and less expensive. As a result, the relative benefits of short-interval follow-up MRI versus percutaneous needle sampling are less than the benefits of follow-up mammography versus intraoperative excision.
We hope to further define the MRI BI-RADS 3 assessment category through our experience. Our results may suggest which lesions are appropriate for short-term follow-up and, alternatively, which lesions are not appropriate for short-term follow-up. In defining the latter, we can suggest which lesions should be assessed BI-RADS 4 or BI-RADS 2.
The largest group of probably benign lesions in our study was composed of foci [18] in which it is divided by the number of probably benign examinations. b Calculated as the number of malignancies divided by the number of patients except for Kriege et al. [18] in which it is divided by the number of probably benign examinations. Note-DCIS = ductal carcinoma in situ, ADH = atypical ductal hyperplasia. NR = not reported, NA = not applicable.
(48%, 168/362), by definition lesions smaller than 5 mm. Prior research indicates that the risk of malignancy in suspicious lesions smaller than 5 mm is less than 3% [20] . The authors concluded: "Biopsy is generally not warranted for MRI-detected lesions less than 5 mm." This statement, as the authors acknowledge, was made without incorporating kinetic information. Our findings, with a larger sample of probably benign foci, support that conclusion. In addition, our kinetic data build on this previous work. We found one malignancy that was initially described as a focus with washout-delayed kinetic enhancement. However, in our study, all 69 foci that showed 100% delayed persistent enhancement were benign. These 69 foci were identified on 55 examinations in 54 patients. If we had called these benign on the baseline examination, the percentage of women recommended for short-term follow-up would have been decreased from 14% (236/1,735) to 10% (182/1,735) and the cancer yield would remain relatively unchanged at 1.1% (2/182) instead of 0.8% (2/236). We could make a similar argument for considering masses that showed 100% persistent enhancement as benign lesions because we did not observe any malignancies within this group. However, compared with foci, we had a significantly smaller sample of Eby et al.
masses. In addition, given the previous research by Liberman et al. [20] that indicates a significantly increased risk of malignancy among lesions larger than 5 mm, the option of short-term follow-up of masses should be preserved until additional data are available.
It should be noted that magnetic field strength could impact clinical results. Our data and that of previous research in probably benign lesions are based on images acquired with 1.5-T machines. Kuhl et al. [21] suggested that kinetic results, especially when analyzed with CAE software, may be significantly different with 3-T scanners because of decreased T1 relaxation and smaller changes in signal intensity before and after contrast administration [21] .
The failure of 38% of our patients to return for the recommended follow-up MRI may be a limitation to our study. However, the link to the regional tumor registry allowed us to check for a diagnosis of malignancy in this group of patients for at least 18 months after the initial MRI. No cases of breast cancer were found to match the BI-RADS 3 lesions. It is possible that a patient could have been diagnosed with breast cancer after moving away from the geographic territory of the tumor registry. In such an unlikely scenario, we would not be aware of the diagnosis or be able to correlate it to a BI-RADS 3 lesion.
Delayed phase kinetic information was missing for 87 (24%) of 362 study lesions, and this may limit our evaluation. We suspect that there are two primary reasons the data are missing for some lesions. The first reason is that the lesion enhancement was below the threshold for detection by the CAE software. The second reason is failure to record the data on the part of the radiologist at the time of interpretation.
In conclusion, the characteristics of BI-RADS 3 lesions are highly variable in our population, with a cancer yield of 0.8%. By assigning foci with 100% persistent enhancement to the BI-RADS 2 category, the utilization of the BI-RADS 3 assessment and short-term follow-up MRI could be decreased from 14% of patients to 10% of patients while still maintaining a cancer yield of less than 2%. Fig. 2 -Sequential sagittal images from T1-weighted fat-suppressed dynamic contrast-enhanced MRI in 44-year-old woman who was followed with sequential short-term examinations for 20 months. MRI-guided biopsy revealed high-grade ductal carcinoma in situ (DCIS). A, Focus (arrow) is described and assessed as BI-RADS 3, with 6-month follow-up MRI recommended. B, First follow-up MRI reveals same focus (arrow). BI-RADS 3 assessment was given, with recommendation for 6-month follow-up MRI. C, Second follow-up MRI, now 13 months after baseline examination, depicts same focus (arrow), and 6-month follow-up MRI was recommended again. D, Third follow-up MRI, now 20 months after baseline examination, shows nonmasslike enhancement (NMLE) spanning 21 mm at site of focus (arrow). BI-RADS 4 assessment was given, and MRI-guided biopsy was recommended. E, MRI-guided biopsy shows obturator in center of suspicious NMLE (arrow). Diagnosis of high-grade DCIS was made from tissue sample.
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